证券代码：600436 证券简称：片仔癀 公告编号：2025-038 漳州片仔癀药业股份有限公司关于 PZH2108 片 Ⅱa 期临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 漳州片仔癀药业股份有限公司（以下简称"公司"）PZH2108 片Ⅱa期临床试验完成首例受试者入组对公司本年度的财务状况和经 营业绩无重大影响。 由于药品研发的特殊性，具有周期长、环节多、风险大、投入 高的特点，容易受到政策、技术、市场等多方面因素的影响，审评政 策及产品未来市场竞争形势等存在诸多不确定性风险。 公司将密切关注该药物研发事项的后续进展情况，及时履行信 息披露义务。敬请广大投资者谨慎决策，注意防范投资风险。 近日，公司研发的化学药品 1 类创新药 PZH2108 片完成"一项在 肿瘤患者中评价 PZH2108 片的安全性、耐受性、初步临床有效性、药 代动力学及药效学特征的多中心、随机、双盲、安慰剂对照Ⅱa 期临 床研究"首例受试者入组，正式进入Ⅱa 期临床试验。现将相关内容 公告如下： 一、 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-042 漳州片仔癀药业股份有限公司 (一) 股东大会类型和届次 2025年第一次临时股东大会 召开日期时间：2025 年 12 月 9 日 09 点 00 分 1 / 8 股东大会召开日期：2025年12月9日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 (四) 现场会议召开的日期、时间和地点 召开地点：漳州市芗城区姜园亭 78 号片仔癀温泉酒店二楼圆山厅 (五) 网络投票的系统、起止日期和投票时间。 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 9 日 至2025 年 12 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时 ...

股票代码：600436 股票简称：片仔癀 漳州片仔癀药业股份有限公司 2025 年第一次临时股东大会会议材料 福建·漳州 二〇二五年十二月九日 0 漳州片仔癀药业股份有限公司 2025 年第一次临时股东大会事项、表决方法说明 各位股东、股东代表： 根据《漳州片仔癀药业股份有限公司章程》（以下简称"《公司章程》"） 等相关规定，漳州片仔癀药业股份有限公司（以下简称"公司"）2025 年 第一次临时股东大会的会议事项、投票表决等规定如下： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对，请被核对者给予配合。 二、股东及股东代表应于会议开始前入场；中途入场者，应经会议工作 人员的许可。 三、股东参加股东大会依法享有发言权、质询权、表决权等权利。股东 参加股东大会应认真履行其法定义务，不得侵犯公司和其他股东的合法权 益，不得扰乱股东大会的正常秩序。 四、股东及股东代表要求发言时，应当按照会议的议程，经会议主持人 许可方可发言。有多名股东同时要求发言时，先举手者发言；不能确定先 后时，由主持人指定发言者。会议进行中只接受股东及股东代表发言或提 问，其发言或提问 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-039 漳州片仔癀药业股份有限公司 第七届董事会第三十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届董事 会第三十六次会议于 2025 年 11 月 19 日（星期三）上午 09：00 在 片仔癀大厦 23 楼会议室以通讯方式召开。会议通知和议案以专人送 达、电子邮件方式发出。本次会议应参加表决的董事 6 人，实际表 决的董事 6 人。会议召开符合《公司法》《漳州片仔癀药业股份有限 公司公司章程》的有关规定，合法、有效，会议由董事长林志辉先 生主持。经审议，与会董事以通讯方式表决以下议案： 一、审议通过《关于撤销监事会暨修订<公司章程>的议案》； 出席会议的董事 6 票同意，0 票反对，0 票弃权。 议案内容详见公司同日在上海证券交易所网站披露的《公司关 于修订<公司章程>的公告》（2025-040 号）。 该议案尚需提交至公司股东大会审议。 二、审议通过《关于修订<股东会议事规则>的议案》； ...

Core Viewpoint - The company Pianzaihuang (600436.SH) has announced the initiation of a Phase IIa clinical trial for its innovative chemical drug PZH2108, which aims to evaluate safety, tolerability, preliminary clinical efficacy, pharmacokinetics, and pharmacodynamics in cancer patients [1] Group 1 - The Phase IIa clinical trial is a multicenter, randomized, double-blind, placebo-controlled study [1] - The first subject has been enrolled in the trial, marking a significant milestone for the company's research and development efforts [1]

Core Viewpoint - The company Pianzaihuang (片仔癀) has announced the successful enrollment of the first subject in the Phase IIa clinical trial for its innovative chemical drug PZH2108, aimed at treating cancer-related pain [2]. Group 1: Drug Development - PZH2108 has completed the enrollment of the first subject in its Phase IIa clinical trial [2]. - The total research and development investment for PZH2108 has reached approximately 61 million yuan [2]. - As of the announcement date, no other companies have obtained production licenses for this product, and there are no approved drugs targeting the same indication as PZH2108 [2].

Core Viewpoint - The company, Pianzihuang (600436.SH), has announced that its innovative chemical drug PZH2108 has completed the enrollment of the first subject in the Phase IIa clinical trial, aimed at treating cancer pain [1] Company Summary - The cumulative research and development investment for PZH2108 has reached approximately 61 million yuan [1] - As of the announcement date, no other companies have obtained production licenses for this product, and there are no approved drugs targeting the same indication as PZH2108 [1]

片仔癀公告称，董事会于近日收到施艺雄书面辞职报告，其因工作分工调整，于11月19日辞去董事会秘 书职务，原定任期至2025年1月20日，辞职后仍任公司副总经理。施艺雄已做好交接工作，其离任不会 对公司产生不利影响。此外，经公司第七届董事会第三十六次会议审议通过，何炜被聘为公司董事会秘 书，任期与第七届董事会一致。 ...

Group 1: Performance Overview - The performance of Pian Zai Huang has significantly declined, with a 11.93% drop in revenue and a 20.74% decrease in net profit for the first three quarters of 2025, marking the worst performance in a decade [3][4] - In contrast, Moutai has shown resilience, achieving an 8.09% increase in revenue and an 8.88% rise in net profit during the same period, maintaining a solid growth trajectory despite industry pressures [12][13] Group 2: Market Dynamics - Pian Zai Huang's stock price has plummeted from 473 yuan to 176 yuan, resulting in a market capitalization loss exceeding 200 billion yuan, while the company has underperformed the market by approximately 31% [4][7] - The price of Pian Zai Huang's core product has collapsed, with market prices dropping from 1600 yuan per piece in 2021 to around 400-500 yuan, leading to significant inventory accumulation [8][10] Group 3: Regional Performance - Revenue has declined across most regions for Pian Zai Huang, with only South China and Northwest regions showing slight growth, indicating a broader market contraction [9][11] - Moutai, however, has maintained its market leadership and brand loyalty, effectively navigating the challenges posed by declining prices and overall market conditions [16][18] Group 4: Consumer Behavior Changes - The decline of the "Old Deng Economy" has led to a significant reduction in traditional consumption scenarios, with a 23% drop in terminal opening rates and nearly 30% decrease in wedding and business banquet settings [20][22] - Younger consumers show a lack of interest in traditional high-end liquor and health products, with only 15% of Gen Z engaging in liquor consumption compared to 40% of older generations [22][23] Group 5: Future Strategies - Pian Zai Huang needs to refocus on its core pharmaceutical value, emphasizing clinical research and product innovation to adapt to market changes [25] - Moutai aims to balance its high-end positioning while expanding into broader consumer markets, enhancing its global presence and product offerings to meet diverse consumer needs [26]

Core Viewpoint - The report from Western Securities indicates that the company's net profit attributable to shareholders for Q1-Q3 2025 is 2.129 billion yuan, a decrease of 20.74%, with Q3 net profit at 688 million yuan, down 28.82% [1] Financial Performance - The company's revenue and gross margin are under short-term pressure, but improvements in gross margin are expected due to the price drop of natural bezoar [1] - The core product, "Pian Zai Huang," is available in two forms: pill and capsule, both having the same ingredients and therapeutic functions [1] Product Development and Market Expansion - The company is focused on expanding its product line, including "Yin Dan Ping Gan Capsules," "Compound Pian Zai Huang Tablets," "Chuan Bei Qing Fei Syrup," and "Compound Pian Zai Huang Ointment" [1] - The beauty segment is performing well, with the star product "Empress Pearl Cream" achieving a sales increase of 60% year-on-year in the first half of 2025 [1] Research and Development - In October, the company completed the first subject enrollment for the Phase III clinical trial of its innovative traditional Chinese medicine, "Wen Dan Pian," targeting mild to moderate generalized anxiety disorder [1] Strategic Partnerships - The company is enhancing its channel development by establishing strategic partnerships with several leading chain pharmacies, including Yifeng, achieving coverage of over 100,000 terminal stores [1] Investment Rating - The core product series of Pian Zai Huang possesses rare attributes, and the company maintains an "overweight" rating [1]